15289-s-bos

1 15 | Introduction 23. MeijboomWB, van Mieghem CA, Mollet NR et al. 64-slice computed tomography coronary angiography in patients with high, intermediate, or low pretest probability of significant coronary artery disease. J Am Coll Cardiol 2007;50:1469-75. 24. Choi EK, Choi SI, Rivera JJ et al. Coronary computed tomography angiography as a screening tool for the detection of occult coronary artery disease in asymptomatic individuals. J Am Coll Cardiol 2008;52:357-65. 25. Neefjes LA, Ten Kate GJ, Rossi A et al. CT coronary plaque burden in asymptomatic patients with familial hypercholesterolaemia. Heart 2011;97:1151-7. 26. Ten Kate GJ, Neefjes LA, Dedic A et al. The effect of LDLR-negative genotype on CT coronary atherosclerosis in asymptomatic statin treated patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2013;227:334-41. 27. Lindroos M, Kupari M, Heikkila J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 1993;21:1220-5. 28. Owens DS, Budoff MJ, Katz R et al. Aortic valve calcium independently predicts coronary and cardiovascular events in a primary prevention population . JACC Cardiovascular imaging 2012;5:619-25. 29. Hoeg JM, Feuerstein IM, Tucker EE. Detection and quantitation of calcific atherosclerosis by ultrafast computed tomography in children and young adults with homozygous familial hypercholesterolemia . Arteriosclerosis and thrombosis : a journal of vascular biology / AmericanHeart Association 1994;14:1066- 74. 30. Awan Z, Alrasadi K, Francis GA et al. Vascular calcifications in homozygote familial hypercholesterolemia. Arteriosclerosis, thrombosis, and vascular biology 2008;28:777-85. 31. Kawaguchi A, Miyatake K, Yutani C et al. Characteristic cardiovascular manifestation in homozygous and heterozygous familial hypercholesterolemia. American heart journal 1999;137:410-8. 32. Pitsavos C, Toutouzas K, Dernellis J et al. Aortic stiffness in young patients with heterozygous familial hypercholesterolemia. American heart journal 1998;135:604-8. 33. Tato F, Keller C, Schewe S, Pinter W, Wolfram G. Echocardiographic changes in patients with heterozygous and homozygous familial hypercholesterolemia: correlation with clinical findings . Bildgebung = Imaging 1991;58:22-5. 34. Rallidis L, Naoumova RP, Thompson GR, Nihoyannopoulos P. Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia. Heart 1998;80:583-90. 35. Rossebo AB, Pedersen TR, Boman K et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. The New England journal of medicine 2008;359:1343-56. 36. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J, Investigators A. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial . Circulation 2010;121:306-14. 37. Cowell SJ, Newby DE, Prescott RJ et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. The New England journal of medicine 2005;352:2389-97. 38. Versmissen J, Oosterveer DM, Yazdanpanah M et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ (Clinical research ed) 2008;337:a2423. 39. Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics . J Intern Med 2013;273:6-30. 40. SeedM, Hoppichler F, Reaveley D et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. The New England journal of medicine 1990;322:1494-9. 41. Sijbrands EJ, Westendorp RG, Paola Lombardi M et al. Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia. Atherosclerosis 2000;149:421-5. 42. Sijbrands EJ,Westendorp RG, Defesche JC, deMeier PH, Smelt AH, Kastelein JJ. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study . BMJ (Clinical research ed) 2001;322:1019-23. 43. Jansen ACM, Aalst-Cohen ES, Tanck MW et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. Journal of internal medicine 2004;256:482- 490. 44. Nenseter MS, Lindvig HW, Ueland T et al. Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia. Atherosclerosis 2011;216:426-32.